Parallax Volatility Advisers
ACRS icon

Parallax Volatility Advisers’s Aclaris Therapeutics ACRS Stock Holding History

Parallax Volatility Advisers’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-48,434
Closed -$392K – 2328
2023
Q1 		$392K Buy
+48,434
New +$615K ﹤0.01% 1802
2019
Q2 		– Sell
-11,100
Closed -$66K – 2476
2019
Q1 		$66K Buy
11,100
+3,300
+42% +$21.9K ﹤0.01% 2210
2018
Q4 		$58K Buy
+7,800
New +$80.4K ﹤0.01% 2074
2018
Q1 		– Sell
-3,486
Closed -$86K – 2142
2017
Q4 		$86K Buy
+3,486
New +$84.9K ﹤0.01% 2888

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parallax Volatility Advisers's ACRS Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 48,434 shares — an estimated $392K sold.

Parallax Volatility Advisers first reported a position in ACRS in Q4 2017 and held it in 4 quarters. The position peaked at $392K in Q1 2023. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • Parallax Volatility Advisers reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 48,434 Aclaris Therapeutics shares in Q2 2023, an estimated $392K.
  • Parallax Volatility Advisers first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 4 quarters.
  • Parallax Volatility Advisers's Aclaris Therapeutics position peaked at $392K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.